
IRON Stock Forecast & Price Target
IRON Analyst Ratings
Bulls say
Disc Medicine is a promising biopharmaceutical company with a solid pipeline targeting diseases related to red blood cells. Their recent Phase 2 data on selcodebart for the treatment of anemia in myelofibrosis (MF) and chronic kidney disease (CKD) showed promising response rates and they plan to hold an end-of-Phase 2 meeting with the FDA by the end of the year. Additionally, they have a collaboration with Roche and a potential 2032 launch for DISC-3405 in sickle cell disease. With a Buy rating and a price target of $120, Disc has the potential to deliver significant value to investors, but key risks include regulatory approval, commercialization, and financial challenges as they are not yet profitable.
Bears say
Disc Medicine is facing significant challenges and risks in its path to success, with its pipeline still in early stages and only preliminary data available for its lead programs. While the potential for upside exists in the shorter term with the potential early readout of PV data in 3Q26, there are still many unknowns about the clinical efficacy and potential of DISC-3405 and other programs in development, leaving a negative outlook for the company's stock in the longer term.
This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
IRON Analyst Forecast & Price Prediction
Start investing in IRON
Order type
Buy in
Order amount
Est. shares
0 shares